March 12, 2026

Sander Wuyts to Speak at ASA SSGG Webinar on Industry & Commercialization in Statistical Genomics

We are excited to share that ImmuneWatch CEO Sander Wuyts will be a featured speaker at the upcoming ASA Section on Statistical Genetics and Genomics (SSGG) MEC Webinar on Industry & Commercialization in Statistical Genomics.

The online event takes place on Friday, March 27, from 11:00 AM to 12:00 PM ET, and will bring together biotech founders and scientific leaders to discuss the translation of statistical and genomics research into real-world products and companies.

Sander will join a distinguished panel including Keith A. Crandall (seqSight) and Mo Jain, MD PhD (Sapient) to share insights on topics such as:

Research commercialization opportunities
Leadership lessons from biotech founders
Funding pathways
Productizing statistical methods

This is a great opportunity to hear how ImmuneWatch has been turning cutting-edge TCR specificity research into a platform that is redefining immune monitoring for therapeutics and vaccine development.

Stay up to date

Subscribe to our newsletter to receive useful tips and information.

Thank you! Your submission has been received!

Oups ! Un problème s'est produit lors de l'envoi du formulaire.

Recommended articles

July 29, 2024

ImmuneWatch Validates their Expertise in TCR Specificity Prediction in an Independent Machine Learning Competition

We are excited to share our recent win in the IMMREP23 Kaggle competition focused on TCR (T-cell receptor) specificity prediction. This win is a testament to our team’s expertise in implementing advanced machine learning in immunology.

December 15, 2025

New Repertoire Room Podcast Episode: Lucas Arruda (Curacell) on Tackling Cold Solid Tumors with TIL Therapy

In this episode, our host Sander Wuyts sits down with Lucas Arruda, Chief Scientific Officer at Curacell, a Swedish clinical-stage biotech company. Curacell is taking on one of the biggest challenges in oncology: developing effective Tumor Infiltrating Lymphocyte (TIL) therapies for "cold" solid tumors.